Plexus (PLXS) reported earnings 30 days ago. What's next for the stock?
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Plexus (PLXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Plexus (PLXS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Plexus (PLXS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Plexus is delivering faster growth, higher earnings and wider margins, but premium valuation and weaker near-term cash flow temper the buy case.
PLXS' broad Q3 beat and stronger growth outlook extend its runway, but rising working-capital needs put free cash flow conversion under scrutiny.
Plexus NASDAQ: PLXS reported record fiscal third-quarter revenue of $1.305 billion, exceeding its guidance range and rising 12% sequentially and 28% from a year earlier, as demand strengthened across its aerospace and defense, healthcare life sciences, and industrial markets.
PLXS beats fiscal Q3 estimates as revenues jump 28%, fueled by Industrial strength, program ramps and broad demand, while its outlook signals more growth.
Although the revenue and EPS for Plexus (PLXS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Plexus (PLXS) came out with quarterly earnings of $2.32 per share, beating the Zacks Consensus Estimate of $2.1 per share. This compares to earnings of $1.9 per share a year ago.
Plexus (PLXS) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.